DERCUNIMIX
देश: पुर्तगाल
भाषा: अंग्रेज़ी
स्रोत: HMA (Heads of Medicines Agencies)
उत्पाद विशेषताएं
(SPC)
09-05-2012
इस उत्पाद के लिए कुछ दस्तावेज़ वर्तमान में उपलब्ध नहीं हैं, आप हमारी ग्राहक सेवा को अनुरोध भेज सकते हैं और जैसे ही हम उन्हें प्राप्त करने में सक्षम होंगे, हम आपको सूचित करेंगे।
अनुरोध भेजा।
अनुरोध भेजा।
सक्रिय संघटक:
Inactivated Rabbit haemorrhagic Disease 5 PD90, myxomatosis virus attenuated 2.7 log10 CCID50
थमां उपलब्ध:
Merial
ए.टी.सी कोड:
QI08AH01
फार्मास्यूटिकल फॉर्म:
Lyophilisate and Solvent
चिकित्सीय समूह:
live myxomatosis virus + inactivated rabbit haemorrhagic disease virus
चिकित्सीय क्षेत्र:
Rabbit
प्राधिकरण की तारीख:
2012-02-24
उत्पाद विशेषताएं
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
DERCUNIMIX
Lyophilisate and suspension for suspension for injection for rabbits
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
For one dose of vaccine (0.2 ml):
_Lyophilisate _
Attenuated myxomatosis virus, SG33 strain, at least.............................................. 2.7 log
10
CCID50*
* Cell Culture Infective Dose 50%
_Suspension _
Inactivated Viral Haemorrhagic Disease (VHD) virus, AG88 strain .....................................5 PD90*
Adjuvant:
Al
3+
ions (in the form of aluminium hydroxide) ................................................................... 0.350 mg
Excipient:
Thiomersal....................................................................................................................... 0.010 mg
* PD90 : q.s. to obtain the protection of at least 9
animals out of 10 vaccinated with 1/5
th
of dose.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate and suspension for suspension for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Rabbits.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In future breeders from the age of 10 weeks and in breeders:
-
For primary and booster immunisation to reduce mortality caused by Viral Haemorrhagic Disease
of rabbits.
-
For booster immunisation to prevent mortality caused by myxomatosis.
Immunity against VHD has been demonstrated 1 week after vaccination and persists during one year.
Immunity against myxomatosis persists during 4 months.
4.3
CONTRAINDICATIONS
None
4.4
SPECIAL WARNINGS
None.
3
4.5
SPECIAL PRECAU
पूरा दस्तावेज़ पढ़ें
